European Medicines Agency - Withdrawals of Application - Medicinal Products for Human Use - Ixempra

London, 19 March 2009
Doc. Ref. EMEA/177056/2009
PRESS RELEASE
Bristol-Myers Squibb Pharma EEIG withdraws its marketing authorisation application for Ixempra (ixabepilone)
The European Medicines Agency has been formally notified by Bristol-Myers Squibb Pharma EEIG of its decision to withdraw the application for a centralised marketing authorisation for Ixempra (ixabepilone), 2 mg/ml powder and solvent for concentrate for solution for infusion.

abrir aquí para acceder al documento completo:
European Medicines Agency - Withdrawals of Application - Medicinal Products for Human Use - Ixempra